AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Develops medical devices for kidney stone treatment and removal
Develops treatments for patients suffering from thromboembolic disease
Pitching Ally Bridge Group? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room